Numerous cutaneous adverse effects (CAEs) have been reported with glucose-lowering medications (e.g. insulin, dipeptidyl peptidase4 inhibitors and sulfonylureas) and medical devices (e.g. continuous subcutaneous insulin infusion and continuous glucose monitoring) used in the management of diabetes. ...